comparemela.com

Latest Breaking News On - Newtyn management - Page 1 : comparemela.com

Visionary Wealth Advisors Boosts Stake in PAR Technology Co (NYSE:PAR)

Visionary Wealth Advisors raised its position in PAR Technology Co. (NYSE:PAR – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 317,938 shares of the software maker’s stock after buying an additional 8,635 shares during the period. PAR Technology accounts […]

Theravance Biopharma (NASDAQ:TBPH) Lowered to Hold at StockNews com

StockNews.com lowered shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) from a buy rating to a hold rating in a report issued on Tuesday morning. Several other equities analysts have also commented on TBPH. HC Wainwright reaffirmed a buy rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research report […]

Adverum Biotechnologies, Inc (NASDAQ:ADVM) Receives Consensus Rating of Buy from Analysts

Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) has received an average rating of “Buy” from the four brokerages that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the […]

Theravance Biopharma (NASDAQ:TBPH) Upgraded at StockNews com

StockNews.com upgraded shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) from a hold rating to a buy rating in a research report report published on Monday. Several other equities research analysts also recently commented on the stock. BTIG Research began coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They […]

Bolt Biotherapeutics (NASDAQ:BOLT) Receives Market Perform Rating from SVB Leerink

SVB Leerink reissued their market perform rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT – Free Report) in a research report released on Wednesday morning, Benzinga reports. SVB Leerink currently has a $1.00 price target on the stock, down from their previous price target of $3.00. Several other research analysts have also recently commented on BOLT. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.